 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...79808182838485868788899091» |
- || levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
New P3 trial: Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide (clinicaltrials.gov) - Apr 21, 2014
P3, N=100, Recruiting, Sponsor: Huashan Hospital
- levofloxacin / Generic mfg., erythromycin / Generic mfg.
Trial completion: CAP-START: Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=2283, Completed, Sponsor: UMC Utrecht
Active, not recruiting --> Completed
- | levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
Enrollment open: Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide (clinicaltrials.gov) - Apr 20, 2014
P3, N=100, Recruiting, Sponsor: Huashan Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P4 trial: C H R O N O S: Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis (clinicaltrials.gov) - Apr 14, 2014
P4, N=40, Completed, Sponsor: Tourcoing Hospital
- |||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment open: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Apr 2, 2014
P3, N=840, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- linezolid oral / Generic mfg.
Clinical data: PRESTO:Osteo: Patients Response to Early Switch To Oral:Osteomyelitis Study (clinicaltrials.gov) - Mar 26, 2014
P0, N=456, Not yet recruiting, Sponsor: Julio Ramirez
- ||||| Vesicare (solifenacin) / Astellas
New P4 trial: The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females (clinicaltrials.gov) - Mar 20, 2014
P4, N=126, Recruiting, Sponsor: Dr Cipto Mangunkusumo General Hospital
- | Noxafil (posaconazole) / Merck (MSD)
Enrollment open: Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=1000, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting
- levofloxacin / Generic mfg., fluconazole oral / Generic mfg., itraconazole / Generic mfg.
Clinical: Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=1000, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | levofloxacin / Generic mfg.
New P2 trial: Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD (clinicaltrials.gov) - Feb 18, 2014
P2, N=300, Recruiting, Sponsor: University of Monastir
- Beova (vibegron) / Merck (MSD), Kissei, Kyorin, Sumitomo Pharma, Pierre Fabre
Enrollment change: A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) (clinicaltrials.gov) - Feb 2, 2014
P1, N=4, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=40 --> 4
- Beova (vibegron) / Merck (MSD), Kissei, Kyorin, Sumitomo Pharma, Pierre Fabre
Trial termination: A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) (clinicaltrials.gov) - Jan 20, 2014
P1, N=4, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=40 --> 4 Suspended --> Terminated; This study was terminated early due to insufficient recruitment.
- ceftriaxone / Generic mfg., levofloxacin / Generic mfg.
Clinical: EVOTAR: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients. (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=300, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||||| levofloxacin / Generic mfg., prednisolone acetate ophthalmic suspension / Generic mfg.
New P4 trial, Surgery: RLOTUS: A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms (clinicaltrials.gov) - Jan 5, 2014
P4, N=180, Completed, Sponsor: Allergan
- | New P2 trial: Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis (clinicaltrials.gov) - Dec 29, 2013
P2, N=128, Not yet recruiting, Sponsor: Vanderbilt University
- | levofloxacin / Generic mfg.
New P4 trial: Pharmacokinetics of Levofloxacin in Intensive Care Unit (clinicaltrials.gov) - Dec 19, 2013
P4, N=65, Recruiting, Sponsor: University Hospital, Toulouse
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment change: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication (clinicaltrials.gov) - Nov 30, 2013
P4, N=618, Completed, Sponsor: National Taiwan University Hospital
Suspended --> Terminated; This study was terminated early due to insufficient recruitment. N=800 --> 618
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Trial completion: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication (clinicaltrials.gov) - Nov 30, 2013
P4, N=618, Completed, Sponsor: National Taiwan University Hospital
N=800 --> 618 Recruiting --> Completed
- || levofloxacin / Generic mfg.
New P3 trial: Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations (clinicaltrials.gov) - Nov 18, 2013
P3, N=70, Recruiting, Sponsor: University of Rochester
- |||||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P3 trial: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Nov 6, 2013
P3, N=840, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
- ||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Trial completion: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis (clinicaltrials.gov) - Sep 29, 2013
P3, N=558, Completed, Sponsor: Cubist Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | gentamicin sulfate / Generic mfg.
New P4 trial, Combination therapy: Efficacy and Safety of Garamycin (clinicaltrials.gov) - Sep 25, 2013
P4, N=144, Recruiting, Sponsor: University Hospital, Geneva
- levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., rifampicin / Generic mfg.
Trial completion, Combination therapy: CLINDOS: Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA) (clinicaltrials.gov) - Sep 16, 2013
P=N/A, N=23, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | levofloxacin / Generic mfg., cloxacillin / Generic mfg.
Enrollment open: Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. (clinicaltrials.gov) - Aug 15, 2013
P3, N=154, Recruiting, Sponsor: Fundaci
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | levofloxacin / Generic mfg.
New P2 trial, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Aug 5, 2013
P2, N=100, Not yet recruiting, Sponsor: Boston University
- levofloxacin / Generic mfg.
Trial completion: CRC-TU-SIGNIFICANT: Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma (clinicaltrials.gov) - Jul 31, 2013
P3, N=0, Completed, Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Enrollment change: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis (clinicaltrials.gov) - Jul 9, 2013
P3, N=525, Completed, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Completed N=776 --> 525
- ||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Trial completion: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis (clinicaltrials.gov) - Jul 9, 2013
P3, N=525, Completed, Sponsor: Cubist Pharmaceuticals
N=776 --> 525 Recruiting --> Completed
- levofloxacin / Generic mfg.
Enrollment closed: Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study (clinicaltrials.gov) - Jul 2, 2013
P4, N=154, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| levofloxacin / Generic mfg., norfloxacin / Generic mfg.
New P4 trial: An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment (clinicaltrials.gov) - Jun 17, 2013
P4, N=119924, Completed, Sponsor: Janssen Research & Development, LLC
- ||||||| Taigexyn (nemonoxacin) / TaiGen
Trial completion: Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP (clinicaltrials.gov) - Jun 16, 2013
P3, N=540, Completed, Sponsor: TaiGen Biotechnology Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- || levofloxacin / Generic mfg., cloxacillin / Generic mfg.
New P3 trial: Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. (clinicaltrials.gov) - Jun 9, 2013
P3, N=154, Recruiting, Sponsor: Fundaci
- levofloxacin / Generic mfg.
Trial withdrawal: Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=0, Withdrawn, Sponsor: Rabin Medical Center
Recruiting --> Completed Recruiting --> Withdrawn
- levofloxacin / Generic mfg.
Enrollment change: Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=0, Withdrawn, Sponsor: Rabin Medical Center
Recruiting --> Withdrawn N=546 --> 0
- levofloxacin / Generic mfg.
New P4 trial: Day/night rhythms in the uptake and elimination of the antibiotic Levofloxacin Een onderzoek naar de dag/nacht ritmes in de opname en afbraak van het antibioticum Levofloxacine. (EUDRACT) - Jun 5, 2013
P4, N=12, Ongoing, Sponsor: Centre for Human Drug Research
- Enrollment change: Levo?oxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection (clinicaltrials.gov) - May 31, 2013
P4, N=200, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
N=546 --> 0 N=100 --> 200
- Trial completion: Levo?oxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection (clinicaltrials.gov) - May 31, 2013
P4, N=200, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
N=100 --> 200 Recruiting --> Completed
- levofloxacin / Generic mfg.
Enrollment open: Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease (clinicaltrials.gov) - Mar 29, 2013
P=N/A, N=120, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| levofloxacin / Generic mfg.
Trial initiation date: A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection (clinicaltrials.gov) - Mar 7, 2013
P3, N=2233, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting Initiation date: Feb 2002 --> Aug 2002
- | New P2 trial: Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection (clinicaltrials.gov) - Mar 4, 2013
P2, N=114, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 11, 2013
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Feb 2002 --> Aug 2002 N=800 --> 1300
- ||||| levofloxacin / Generic mfg., tigecycline / Generic mfg.
Trial initiation date: Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia (clinicaltrials.gov) - Feb 6, 2013
P3, N=434, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
N=800 --> 1300 Initiation date: Sep 2003 --> Jan 2004
- levofloxacin / Generic mfg.
New P1 trial: The Safety of Tuberculosis Treatments by Oral Inhalation (clinicaltrials.gov) - Feb 5, 2013
P1, N=40, Not yet recruiting, Sponsor: Prince of Songkla University
- || levofloxacin / Generic mfg.
New P3 trial: FLISH-ILT: "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". (clinicaltrials.gov) - Jan 2, 2013
P3, N=870, Recruiting, Sponsor: Fundaci
- | Taksta (fusidic acid) / Idera
New P2 trial: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (clinicaltrials.gov) - Dec 26, 2012
P2, N=50, Recruiting, Sponsor: Cempra Pharmaceuticals
- levofloxacin / Generic mfg.
Trial completion: Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Dec 11, 2012
P4, N=161, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Initiation date: Sep 2003 --> Jan 2004 Recruiting --> Completed
- | New P4 trial: Levo?oxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection (clinicaltrials.gov) - Dec 3, 2012
P4, N=200, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
- levofloxacin / Generic mfg.
Trial initiation date: Enteroaggregative E.Coli (EAEC) (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=5, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Initiation date: Dec 2006 --> Feb 2008
- levofloxacin / Generic mfg.
Enrollment change: Enteroaggregative E.Coli (EAEC) (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=5, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Dec 2006 --> Feb 2008 N=25 --> 5
- levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Trial termination: Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients (clinicaltrials.gov) - Nov 21, 2012
P3, N=182, Terminated, Sponsor: Seoul National University Hospital
N=25 --> 5 Recruiting --> Terminated